Global Proteomics Market to Reach USD 67.55 Billion by 2032, Growing at a CAGR of 10.65% During 2026–2032

The global proteomics market was valued at USD 33.45 billion in 2025 and is projected to expand from USD 36.81 billion in 2026 to USD 67.55 billion by 2032, reflecting a robust CAGR of 10.65% during 2026–2032. This sustained growth is driven by expanding applications in precision medicine, oncology diagnostics, and translational drug development, alongside rising investments from pharmaceutical and biotechnology companies in biomarker discovery and protein characterization.

A primary catalyst shaping market expansion is the intensifying demand for personalized and precision medicine, which requires comprehensive protein-level analysis for biomarker identification, therapeutic targeting, and treatment response monitoring. Pharmaceutical companies are increasingly embedding proteomic profiling into targeted drug, biologic, and immunotherapy development pipelines. Furthermore, the US FDA reinforced regulatory emphasis on biomarker qualification and validation through updated guidance frameworks issued in 2025–2026, encouraging broader integration of proteomic data into therapeutic development.

Additionally, the integration of artificial intelligence and multi-omics technologies is emerging as a defining trend reshaping global proteomics workflows. AI-driven platforms such as Google DeepMind AlphaFold 3 have accelerated protein structure prediction and biomarker identification, while companies such as AstraZeneca have applied AI-driven multi-omics analysis on cancer patient datasets to identify protein pathways linked to tumor progression and drug resistance. These developments are advancing automated bioinformatics adoption across biopharmaceutical and clinical research environments.

From a segmentation perspective, Drug Discovery dominates the application landscape, reflecting high reliance on analytical technologies in early-stage research and development pipelines. Moreover, Spectroscopy leads the technology segment, supported by widespread adoption in molecular characterization, quantitative proteomics, and bioanalytical studies. Thermo Fisher Scientific's Orbitrap Astral Zoom and Orbitrap Excedion Pro platforms, introduced in 2025, exemplify sustained commercial investment in high-throughput analytical instrumentation.

Regionally, North America leads the global proteomics market with approximately 45% share, underpinned by strong pharmaceutical research and development infrastructure, federal funding through the National Institutes of Health, and high concentration of contract research organizations and academic medical centers. The NIH-backed TOPMed initiative and the Human BioMolecular Atlas Program (HuBMAP) continue to reinforce large-scale proteomics adoption. Consequently, North America remains the primary hub for proteomics innovation, commercialization, and clinical translation globally, as stated in the recent report “Global Proteomics Market Analysis, 2026”.

Global Proteomics Market Highlights

The global proteomics market was valued at USD 33.45 billion in 2025, projected to grow from USD 36.81 billion in 2026 to USD 67.55 billion by 2032, at a CAGR of 10.65% during 2026–2032.
North America leads the global proteomics market with a 45% share, driven by strong pharmaceutical research and development infrastructure and advanced research ecosystems.
Drug Discovery remains the dominant application segment with a 53% share, reflecting high reliance on proteomic analytical technologies in early-stage research and development pipelines.
Spectroscopy accounts for 32% share by technology, supported by widespread adoption in molecular characterization and bioanalytical studies.
The global proteomics market is moderately consolidated, with the top five players collectively holding approximately 60% of the global market share.